Deslande v. Fortrea Holdings Inc. — Entry #64

Case: Deslande v. Fortrea Holdings Inc. nysd · 1:25-cv-04630

filed June 02, 2025

What this document is

Docket entry #64 · filed January 28, 2026

Who is involved

City of Boca Raton Police and Firefighters Retirement System
City of Pontiac Reestablished General Employees' Retirement System
Construction Industry Laborers Pension Fund
Fortrea Holdings Inc.
Jill McConnell
Lucas Deslande
Nova Scotia Public Service Superannuation Plan
Nova Scotia Teachers' Pension Plan
Stefan Muenchhagen
Thomas Pike

Why we have it

We follow this case because it names a company we track, although that company is not a party:

Hut 8: its name “Hut 8 Corp.” appears in a filing in this case.
…Plaintiff, v. HUT 8 CORP., JAIME LEVERTON, and SHENIF VISRAM,…
CleanSpark: its name “CleanSpark, Inc.” appears in a filing in this case.
…2019) ...........................7 Bishins v. CleanSpark, Inc., No. 21 CV 511 (LAP), 2023 WL 112558…

A free copy from the RECAP archive of federal court filings (mirrored at the Internet Archive), retrieved September 28, 2026. Federal court filings are public records.

URL: https://archive.org/download/gov.uscourts.nysd.643614/gov.uscourts.nysd.643614.64.0.pdf
Kind: court_filing
Publisher: RECAP
Retrieved: 2026-09-28 05:58:16.177061-04:00
HTTP status: 200
MIME: application/pdf
Bytes: 358613
SHA-256: 45dec3649642ce5ce705d14cd521cf2005907f8319d07ec196e351b4c506934d

Document text

36 page(s), 83,839 characters, converted from the PDF's text layer · plain text.

Full text

Case 1:25-cv-04630-KPF Document 64 Filed 01/28/26 Page 1 of 36

UNITED STATES DISTRICT COURT
SOUTHERN DISTRICT OF NEW YORK
----------------------------------- x
LUCAS DESLANDE, Individually and on :
Behalf of All Others Similarly Situated, :
: Civil Action No. 1:25-cv-04630-KPF
Plaintiff, :
:
vs. :
:
FORTREA HOLDINGS INC., THOMAS PIKE,:
and JILL MCCONNELL, :
:
Defendants. :
:
----------------------------------- x

MEMORANDUM OF LAW IN SUPPORT OF DEFENDANTS’
MOTION TO DISMISS THE AMENDED COMPLAINT

Susan L. Saltzstein
Robert A. Fumerton
Jeffrey S. Geier
Eryn M. Hughes
SKADDEN, ARPS, SLATE,
MEAGHER & FLOM LLP
One Manhattan West
New York, New York 10001
(212) 735-3000

Attorneys for Defendants Fortrea Holdings Inc.,
Thomas Pike, and Jill McConnell

Case 1:25-cv-04630-KPF Document 64 Filed 01/28/26 Page 2 of 36

TABLE OF CONTENTS

Page

TABLE OF AUTHORITIES ....................................................................................................... iii

PRELIMINARY STATEMENT ................................................................................................... 1

STATEMENT OF FACTS............................................................................................................ 3

A. Fortrea’s Business and Spin-off from Labcorp.......................................................... 3

B. Fortrea Publicly Disclosed the Transition Plan, the TSA Framework, and
Execution Risk ...................................................................................................... 4

C. Fortrea Explained that TSA Exit Would Be a Step Towards Expected
SG&A Cost Improvements................................................................................... 5

D. Fortrea’s Backlog and PSPs ................................................................................. 6

E. Fortrea Discloses Financial Results and Updates Projections ................................ 7

ARGUMENT .............................................................................................................................. 7

I. PLAINTIFFS FAILS TO PLEAD THE EXISTENCE OF AN ACTIONABLE
MISSTATEMENT OR OMISSION................................................................................... 8

A. The Vast Majority of the Challenged Statements Are Inactionable
Forward-Looking Statements ............................................................................... 9

1. These Forward-Looking Statements Were Accompanied By
Meaningful Cautionary Language ........................................................... 10

2. Plaintiffs Have Not Pled Defendants Had Actual Knowledge That
The Statements Were False..................................................................... 11

B. Plaintiffs’ TSA Allegations Do Not Identify Any Actionable
Misstatement or Omission .................................................................................. 12

C. Plaintiffs’ PSP Allegations Do Not Identify Any Actionable Misstatement
or Omission ....................................................................................................... 17

D. Fortrea’s Statements of Corporate Optimism or Opinion Are Not
Actionable.......................................................................................................... 20

II. PLAINTIFFS FAIL TO ALLEGE A STRONG INFERENCE OF SCIENTER ................... 21

A. Plaintiffs’ Miscellaneous Allegations Do Not Give Rise to a Strong
Inference of Scienter .......................................................................................... 21

Case 1:25-cv-04630-KPF Document 64 Filed 01/28/26 Page 3 of 36

B. The Former Employee Allegations Do Not Establish Scienter ................................. 23

C. Non Culpable Inferences Are More Compelling ................................................. 25

III. PLAINTIFFS FAIL TO PLEAD LOSS CAUSATION .................................................. 25

IV. PLAINTIFFS’ SECTION 20(A) CLAIM SHOULD BE DISMISSED ........................... 26

CONCLUSION.......................................................................................................................... 27

Case 1:25-cv-04630-KPF Document 64 Filed 01/28/26 Page 4 of 36

TABLE OF AUTHORITIES

Page(s)

CASES

Abramson v. Newlink Genetics Corp.,
965 F.3d 165 (2d Cir. 2020) ...................................................................................................... 21

Ark. Public Employees Retirement System v. Bristol-Myers Squibb Co.,
28 F.4th 343 (2d Cir. 2022) ....................................................................................................... 10

ATSI Communications, Inc. v. Shaar Fund, Ltd.,
493 F.3d 87 (2d Cir. 2007) ................................................................................................ 3, 7, 25

In re Barrick Gold Corp. Securities Litigation,
341 F. Supp. 3d 358 (S.D.N.Y. 2018) ........................................................................................ 22

Bay Harbour Management LLC v. Carothers,
282 F. App’x 71 (2d Cir. 2008) ................................................................................................. 16

Bratusov v. Comscore, Inc.,
2020 WL 3447989 (S.D.N.Y. June 24, 2020) ...................................................................... 16, 23

Campo v. Sears Holdings Corp.,
635 F. Supp. 2d 323 (S.D.N.Y. 2009), aff’d, 371 F. App’x 212 (2d Cir. 2010) .......................... 22

Chapman v. Mueller Water Products, Inc.,
466 F. Supp. 3d 382 (S.D.N.Y. 2020) ........................................................................................ 24

In re Chicago Bridge & Iron Co. N.V. Securities Litigation,
2018 WL 2382600 (S.D.N.Y. May 24, 2018) .............................................................................. 9

In re Citigroup Inc. Securities Litigation,
753 F. Supp. 2d 206 (S.D.N.Y. 2010) ........................................................................................ 22

City of Providence v. Aeropostale, Inc.,
2013 WL 1197755 (S.D.N.Y. Mar. 25, 2013) .............................................................................. 9

City of Warren Police & Fire Retirement System v. Foot Locker, Inc.,
412 F. Supp. 3d 206 (E.D.N.Y. 2019)........................................................................................ 20

Damri v. LivePerson, Inc.,
772 F. Supp. 3d 430 (S.D.N.Y. 2025) ........................................................................................ 23

In re Danimer Sci., Inc. Sec. Litig., 2023 WL 6385642 (E.D.N.Y. Sept. 30, 2023), aff’d
sub nom. Swanson v. Danimer Sci., Inc., 2024 WL 4315109 (2d Cir. Sept. 27, 2024) ................ 11

iii

Case 1:25-cv-04630-KPF Document 64 Filed 01/28/26 Page 5 of 36

Docdeer Foundation v. BioNTech SE,
2025 WL 2781381 (S.D.N.Y. Sept. 30, 2025) ................................................... 10, 17, 20, 22, 26

In re DraftKings Inc. Securities Litigation,
650 F. Supp. 3d 120 (S.D.N.Y. 2023) ........................................................................................ 19

In re DRDGOLD Ltd. Securities Litigation,
472 F. Supp. 2d 562 (S.D.N.Y. 2007) .......................................................................................... 7

Dura Pharmaceuticals, Inc. v. Broudo,
544 U.S. 336 (2005) .............................................................................................................. 1, 25

ECA, Local 134 IBEW Joint Pension Trust of Chicago v. JPMorgan Chase Co.,
553 F.3d 187 (2d Cir. 2009) .......................................................................................... 20, 21, 22

In re Estée Lauder Co., Inc. Securities Litigation,
2025 WL 965686 (S.D.N.Y. Mar. 31, 2025) ................................................................................ 9

In re Express Scripts Holdings Co.,
773 F. App’x 9 (2d Cir. 2019) ................................................................................................... 12

In re Farfetch Ltd. Securities Litigation,
802 F. Supp. 3d. 652 (S.D.N.Y. 2025) ....................................................................................... 22

Fila v. Pingtan Marine Enterprise Ltd.,
195 F. Supp. 3d 489 (S.D.N.Y. 2016) ........................................................................................ 25

Fresno County Employees’ Retirement Ass’n v. comScore, Inc.,
268 F. Supp. 3d 526 (S.D.N.Y. 2017) ........................................................................................ 21

Glaser v. The9, Ltd.,
772 F. Supp. 2d 573 (S.D.N.Y. 2011) .................................................................................. 21, 23

Haw. Structural Ironworkers Pension Trust Fund v. AMC Entertainment Holdings, Inc.,
422 F. Supp.3d 821 (S.D.N.Y. 2019) ......................................................................................... 11

In re IAC/InterActiveCorp Securities Litigation,
478 F. Supp. 2d 574 (S.D.N.Y. 2007) ........................................................................................ 12

In re ITT Educational Services, Inc. Securities& Shareholder Derivatives Litigation,
859 F. Supp. 2d 572 (S.D.N.Y. 2012) ........................................................................................ 19

Jackson v. Halyard Health, Inc.,
2018 WL 1621539 (S.D.N.Y. Mar. 30, 2018) ............................................................................ 23

In re Keyspan Corp. Securities Litigation,
383 F. Supp. 2d 358 (E.D.N.Y. 2003)........................................................................................ 16

Case 1:25-cv-04630-KPF Document 64 Filed 01/28/26 Page 6 of 36

Lattanzio v. Deloitte & Touche LLP,
476 F.3d 147 (2d Cir. 2007) ...................................................................................................... 17

Lentell v. Merrill Lynch & Co.,
396 F.3d 161, 173 (2d Cir. 2005)................................................................................... 15, 18, 25

In re Lions Gate Entertainment Corp. Securities Litigation,
165 F. Supp. 3d 1 (S.D.N.Y. 2016)............................................................................................ 17

Lipow v. Net1 UEPS Technologies, Inc.,
131 F. Supp. 3d 144 (S.D.N.Y. 2011) ........................................................................................ 22

Local No. 38 International Bhd. of Electrical Workers Pension Fund v. American
Express Co.,
724 F. Supp. 2d 447 (S.D.N.Y. 2010), aff’d, 430 F. App’x 63 (2d Cir. 2011) ...................... 22, 23

In re Lululemon Securities Litigation,
14 F. Supp. 3d 553 (S.D.N.Y. 2014), aff’d, 604 F. App’x 62 (2d Cir. 2015) .............................. 18

Macquarie Infrastructure Corp. v. Moab Partners, L.P.,
601 U.S. 257 (2024) .................................................................................................................. 16

Martin v. Quartermain,
732 F. App’x 37 (2d Cir. 2018) ................................................................................................. 12

In re Merrill Lynch & Co. Research Reports Securities Litigation,
568 F. Supp. 2d 349 (S.D.N.Y. 2008) ........................................................................................ 15

In re Merrill Lynch & Co. Research Reports Securities Litigation,
273 F. Supp. 2d 351 (S.D.N.Y. 2003), aff’d, 396 F.3d 161 (2d Cir. 2005) ................................... 3

Meyer v. Organogenesis Holdings Inc.,
727 F. Supp. 3d 368 (E.D.N.Y. 2024)........................................................................................ 23

In re Nokia Corp. Securities Litigation,
2021 WL 1199030 (S.D.N.Y. Mar. 29, 2021) ........................................................................ 8, 20

In re Nokia Oyj (Nokia Corp.) Securities Litigation,
423 F. Supp. 2d 364 (S.D.N.Y. 2006) ........................................................................................ 25

Novak v. Kasaks,
216 F.3d 300 (2d Cir. 2000) ................................................................................................ 18, 23

Omnicare, Inc. v. Laborers District Council Construction Industry Pension Fund,
575 U.S. 175 (2015) ........................................................................................................ 8, 16, 20

In re Omnicom Group, Inc. Securities Litigation,
597 F.3d 501 (2d Cir. 2010) ...................................................................................................... 25

Case 1:25-cv-04630-KPF Document 64 Filed 01/28/26 Page 7 of 36

In re Openwave Systems Securities Litigation,
528 F. Supp. 2d 236 (S.D.N.Y. 2007) ........................................................................................ 17

In re Petrobras Securities Litigation,
116 F. Supp.3d 368 (S.D.N.Y. 2015) ......................................................................................... 20

In re Philip Morris International Inc. Securities Litigation,
89 F.4th 408 (2d Cir. 2023) ......................................................................................................... 7

In re Pretium Resources Inc. Securities Litigation,
256 F. Supp. 3d 459 (S.D.N.Y. 2017), aff’d, 732 F. App’x 37 (2d Cir. 2018) ............................ 24

Prime Mover Capital Partners L.P. v. Elixir Gaming Technologies, Inc.,
548 F. App’x 16 (2d Cir. 2013) ................................................................................................. 26

Rombach v. Chang,
355 F.3d 164 (2d Cir. 2004) .................................................................................... 10, 16, 19, 25

SEC v. Farnsworth,
692 F. Supp. 3d 157 (S.D.N.Y. 2023) ........................................................................................ 20

SEC v. Rio Tinto plc,
41 F.4th 47 (2d Cir. 2022) ........................................................................................................... 8

Steamship Trade Ass’n of Baltimore-International Longshoreman’s Ass’n Pension Fund
v. Olo Inc.,
704 F. Supp. 3d 429 (S.D.N.Y. 2023) ........................................................................................ 11

Schiro v. Cemex, S.A.B. de C.V.,
396 F. Supp. 3d 283 (S.D.N.Y. 2019) ........................................................................................ 24

Setzer v. Omega Healthcare Investors, Inc.,
968 F.3d 204 (2d Cir. 2020) ...................................................................................................... 16

Shemian v. Research In Motion Ltd.,
2013 WL 1285779 (S.D.N.Y. Mar. 29, 2013), aff’d, 570 F. App’x 32 (2d Cir. 2014) ................ 19

Sherman v. Abengoa, S.A.,
156 F.4th 152 (2d Cir. 2025) ..................................................................................................... 24

Singh v. Cigna Corp.,
918 F.3d 57 (2d Cir. 2019) .................................................................................................... 7, 12

In re Skechers USA, Inc. Securities Litigation,
444 F. Supp. 3d 498 (S.D.N.Y. 2020) ........................................................................................ 15

Slayton v. American Express Co.,
604 F.3d 758 (2d Cir. 2010) .............................................................................................. 8, 9, 11

Case 1:25-cv-04630-KPF Document 64 Filed 01/28/26 Page 8 of 36

Smith v. PureCycle Technologies, Inc.,
No. 23-CV-8605 (JGK), 2024 WL 5186586 (S.D.N.Y. Dec. 20, 2024) ..................................... 18

In re STMicroelectronics N.V. Securities Litigation,
2025 WL 2644241 (S.D.N.Y. Sept. 15, 2025) ........................................................................... 12

Tongue v. Sanofi,
816 F.3d 199 (2d Cir. 2016) ...................................................................................................... 20

In re Virtu Financial, Inc. Securities Litigation,
770 F. Supp.3d 482 (E.D.N.Y. 2025)......................................................................................... 20

In re Weight Watchers International Inc. Securities Litigation,
504 F. Supp. 3d 224 (S.D.N.Y. 2020) ........................................................................................ 10

Wilbush v. Ambac Financial Group, Inc.,
271 F. Supp. 3d 473 (S.D.N.Y. 2017) ........................................................................................ 23

STATUTES

15 U.S.C. § 78u-4(b)(1)............................................................................................................... 8

15 U.S.C. § 78u-5(c)(1)......................................................................................................... 9, 11

vii

Case 1:25-cv-04630-KPF Document 64 Filed 01/28/26 Page 9 of 36

Defendants Fortrea Holdings Inc. (“Fortrea” or the “Company”), Thomas Pike, and Jill

McConnell (collectively, “Defendants”) respectfully submit this memorandum of law in support

of their motion to dismiss the Amended Complaint (the “Complaint”) (ECF No. 53).1

PRELIMINARY STATEMENT
This action represents an attempt by Plaintiffs to manufacture a securities fraud action out

of Fortrea’s fully disclosed post-spin-off transition process. As part of Fortrea’s July 2023

separation from Labcorp Holdings, Inc. (“Labcorp”), the Company inherited legacy contracts

and systems and entered into publicly disclosed, time-limited Transition Services Agreements

(“TSAs”) under which Labcorp would continue providing certain services while Fortrea built

infrastructure designed for its standalone business. When Fortrea later encountered execution

challenges and revised its outlook, Plaintiffs filed this action in an attempt to transform the

federal securities laws into a system of “broad insurance against market losses,” an approach the

Supreme Court has expressly rejected. Dura Pharms., Inc. v. Broudo, 544 U.S. 336, 345 (2005).

Unfortunately for Plaintiffs, the Complaint does not come close to satisfying the heightened

pleading standards applicable to securities claims and should be dismissed in its entirety.

In support of their legally insufficient Complaint, Plaintiffs advance two theories of

falsity. First, the bulk of the Complaint is directed at Fortrea’s forward-looking statements

concerning the fully-disclosed TSAs, pursuant to which Labcorp (which is not a global

technology or administrative service provider) would continue to provide certain services to

Fortrea during the transition. Plaintiffs point to forward looking statements regarding selling,

1
Citations to the Complaint are in the form of “¶ __.” Exhibits attached to the Declaration of Robert A. Fumerton
are cited herein as “Ex. __.” Pincites for all exhibits reference the original pagination at the bottom of the page.
All internal quotation marks and citations are omitted, and all emphases in quotations are added, unless
otherwise indicated.

Case 1:25-cv-04630-KPF Document 64 Filed 01/28/26 Page 10 of 36

general, & administrative expenses (“SG&A”) and margin improvements that Fortrea foresaw

for coming years as it became a standalone company, and attempt to recast those statements into

guarantees that exiting the TSAs would provide instant cost savings and margin improvements.

In reality, Fortrea properly distinguished between one-time costs and ongoing targets and

explained that it anticipated future SG&A and margin improvements would follow exiting the

TSA and deployment of its new built-for-purpose systems. The Company also disclosed that its

anticipated margin improvements would flow from several different drivers, including improved

revenue. The Complaint confuses one-time and ongoing costs within SG&A and Plaintiffs have

not adequately alleged the falsity of any of Fortrea’s actual statements.

Plaintiffs’ alternate theory is that Fortrea supposedly misled investors about revenue

expected from its backlog of pre-spin projects (“PSPs”). But Plaintiffs do not dispute the

accuracy of Fortrea’s disclosed backlog figures, nor do they allege that Fortrea guaranteed

revenue realization on any particular timeline. Instead, Plaintiffs rely on Fortrea’s later

explanation that certain PSPs were burning more slowly in 2025 than had been expected. Fortrea,

however, consistently disclosed that its backlog consisted of multi-year contracts, that

conversion timing could vary, and that backlog is “not” a “consistent indicator of future

revenue.” (Ex. A at 16, 75; Ex. B at 50; Ex. C at 39; Ex. D at 36; Ex. E at 56.) A later update

about timing does not transform accurate statements into misrepresentations of fact. Once again,

Plaintiffs have not adequately alleged the falsity of any of Fortrea’s actual statements.

Although the Court need not reach the issue given the absence of an actionable false or

misleading statement, Plaintiffs’ claims also fail because they have not pleaded a strong

inference of scienter, much less with the requisite particularity. They allege no motive or stock

sales, or contemporaneous facts showing that Defendants knew any statement was false when

Case 1:25-cv-04630-KPF Document 64 Filed 01/28/26 Page 11 of 36

made. Instead, Plaintiffs rely on vague confidential-witness allegations disconnected from the

allegations of falsity, generalized claims that issues were “well known,” and bald assertions that

Defendants “knew or recklessly disregarded” certain statements were false because of their

positions. (¶¶ 73, 250.) Far from supporting a cogent inference of fraud, the Complaint depicts

management doing exactly what the securities laws contemplate: warning of risks, updating

investors as circumstances evolved, and revising expectations when execution proved more

difficult than anticipated.

Finally, Plaintiffs fail to plead loss causation. None of the events they identify revealed

the falsity of any prior statement, but instead reflect Fortrea’s ongoing disclosures about

execution challenges and evolving, forward-looking expectations during a fully disclosed

transition process.

Given that Plaintiffs fail to plead an actionable misstatement or omission, scienter, or loss

causation, the Complaint should be dismissed in its entirety with prejudice.

STATEMENT OF FACTS2

A. Fortrea’s Business and Spin-off from Labcorp

Fortrea is a global contract research organization (“CRO”) providing clinical

development services to pharmaceutical, biotechnology, and medical device companies. (¶ 2.)

Before July 2023, Fortrea operated as part of Labcorp as its Clinical Development and

Commercialization Services business. (¶ 3.) In June 2023, Fortrea spun off from Labcorp,

becoming a standalone public company. (Id.)

2
The facts set forth herein are drawn from the allegations in the Complaint, documents incorporated by
reference, matters of which judicial notice may be taken, and documents integral to the Complaint. See In re
Merrill Lynch & Co. Rsch. Reps. Sec. Litig., 273 F. Supp. 2d 351, 356-57 (S.D.N.Y. 2003), aff’d, 396 F.3d 161
(2d Cir. 2005). The Court may also consider “legally required public disclosure documents filed with the SEC,
and documents possessed by or known to the plaintiff and upon which it relied in bringing the suit.” ATSI
Commc’ns, Inc. v. Shaar Fund, Ltd., 493 F.3d 87, 98 (2d Cir. 2007).

Case 1:25-cv-04630-KPF Document 64 Filed 01/28/26 Page 12 of 36

B. Fortrea Publicly Disclosed the Transition Plan, the TSA Framework, and Execution Risk

Labcorp’s initial spin announcement explained that “there [would] be ongoing transition

and commercial arrangements to provide for a seamless delivery of services to the customers and

other stakeholders of the Labcorp and the Clinical Development business[.]” (¶ 48.) Among the

multitude of tasks confronting Fortrea, the spin-off required Fortrea to establish independent

systems, infrastructure, and corporate functions that had historically been provided by Labcorp.

(¶¶ 11, 54.) To facilitate the separation, Fortrea entered into a series of TSAs under which

Labcorp would continue to provide certain services–such as information technology, finance,

and human resources–at cost for a limited period while Fortrea built standalone capabilities. (¶¶

52-55.) Fortrea agreed to pay “fees based on the direct and indirect costs associated with

rendering those services, at no less than cost,” and that the TSAs “would not extend later than

June 30, 2025, two years after the effective date of the Spin-Off.” (¶¶ 53, 133.) Thus, from the

very beginning of Fortrea, the market was fully informed of the TSAs, their limited duration and

that services provided thereunder would be billed at Labcorp’s cost. Labcorp, however, is not

alleged to have been a technology service provider, and the systems provided pursuant to the

TSAs had been developed for Labcorp’s business needs, not for Fortrea as a standalone

company.

Fortrea also disclosed that replacing the TSAs would require significant operational

investment: “TSA inefficiencies reflect the impact of the incremental costs of obtaining services

under the transition services agreement compared to the estimated cost of performing those

functions internally.” (Ex. A at 73.) Fortrea also explained that it “anticipated that the TSA

arrangements [would] be phased out over a 24-month period as [Fortrea] develop[ed] the

necessary infrastructure and capabilities to perform these functions internally.” (Id.) Consistent

Case 1:25-cv-04630-KPF Document 64 Filed 01/28/26 Page 13 of 36

with that messaging, Fortrea stated that its near-term capital allocation “prioriti[es]” included

“infrastructure investments to enable timely exit of the TSAs with Labcorp.” (¶ 97.)

C. Fortrea Explained that TSA Exit
Would Be a Step Towards Expected SG&A Cost Improvements

Fortrea repeatedly explained that exiting the TSAs and deploying its newly developed

systems was an important step towards expected future SG&A cost improvements. For example,

during the 3Q23 Earnings Call, Defendant McConnell stated that Fortrea had “detailed plans for

the changes we can make to improve our SG&A cost as a percent of revenue[,]” but that “[t]he

improvements will come in phases over the next few years as some are heavily dependent upon

exit of the TSA agreement.” (¶ 100.) Fortrea cautioned that exiting individual TSAs would not

immediately drive margins: “the ones that we’ve come out [of] aren’t going to—in and of

themselves do a lot in terms of the margin,” because “it’s really what we replace them with.”

(Ex. F at 9.)

Fortrea also explained the larger context of future potential cost savings: “We do need to

invest more in supporting technology and the spin and the exit from the parent will allow us to

completely revise our software suite. There is also an opportunity for greater productivity while

reducing technology costs. We also see procurement facility savings and will align operations

cost with revenues more effectively.” (Ex. G at 8.) The next quarter Fortrea stated, “As we have

mentioned, much of this is focused on reducing high costs in IT, but also improving how we use

technology throughout the business. We will benefit from the more modern tools being deployed

in our industry now, along with AI and automation.” (Ex. H at 7.)

Fortrea also cautioned that forward-looking statements regarding its performance were

subject to “known and unknown risks and uncertainties,” including risks arising from “the

impacts of becoming an independent public company” and its “reliance on Labcorp . . . and third

Case 1:25-cv-04630-KPF Document 64 Filed 01/28/26 Page 14 of 36

parties” for “IT, accounting, finance, legal, human resources, and other services critical to our

businesses” during and following the transition period. (Ex. B at 4; see also Ex. E at 4.) Fortrea

warned that establishing standalone accounting, enterprise resource planning, and other

management systems “could cost more or take longer than anticipated,” and that the operational

and systems separation from Labcorp was “complex and involves numerous systems and

jurisdictions.” (Id.)

D. Fortrea’s Backlog and PSPs

Fortrea also fully disclosed the backlog of PSPs that it inherited following the spin, which

it defined as “anticipated future revenue from business awards that either have not started, or that

are in process and have not been completed.” (¶ 57.) In its FY23 Form 10-K, Fortrea cautioned

that it did “not believe that, as a sole measure, our backlog is a consistent indicator of future

revenue,” because backlog is affected by “the variable size and duration of the projects.” ( Ex. B

at 50.) Similar disclosures were made throughout the putative class period. (See, e.g., Ex. E at

56.) Fortrea also explained that backlog conversion depended on assumptions regarding trial

progress, customer decisions, and contract modifications, that projects “may be canceled or

delayed,” and Fortrea generally has “no contractual right to the full amount of the future revenue

reflected in our backlog” in the event of termination or changes in scope. (Ex. B at 25, 50; Ex. E

at 27.) Fortrea further warned that “[t]he rate at which our backlog converts to revenue may vary

over time,” and that revenue recognition on “larger, more global projects could be slower,”

including due to extended coordination between award and contract execution and delays in

regulatory approvals. (Ex. B at 25; Ex. E at 27.) Fortrea was transparent about revenue pressure

being attributable to the “quantity and burn rate of new business wins pre-Spin” and “challenges

of mix.” (Ex. C at 39; see also Ex. D at 36 (revenues pressured due to “the mix of later stage and

longer duration studies in our portfolio.”).)
6

Case 1:25-cv-04630-KPF Document 64 Filed 01/28/26 Page 15 of 36

E. Fortrea Discloses Financial Results and Updates Projections

Throughout the putative Class Period, Fortrea reported quarterly results reflecting the

costs and operational challenges of operating as a newly independent company. (¶¶ 167-196.) In

May 2024, Fortrea reduced revenue guidance, citing “slower study start-up due to the therapeutic

mix and certain biotech programs” and “lower-than-anticipated first quarter book-to-bill . . . .” (¶

70.) In August 2024, Fortrea revised expectations again, explaining that “the challenges of the

separation and the time it is taking to optimize our commercial approach and operational

execution has led to a slower return to growth and margin expansion than we originally

anticipated.” (Ex. I at 8.) Fortrea confirmed that as it exited the TSAs and implemented its stand-

alone systems, management conducted a “deeper analysis of full-service projects and other

inputs to longer-term forecasts[,]” which took time to confirm and resulted in updated

expectations for 2025. (¶ 280.) With respect to the PSPs, Fortrea disclosed that inherited pre-spin

projects were “extended in duration” and “well into their life cycle,” creating margin headwinds

due to “inefficiencies in the pre-[spin] portfolio and the inherited SG&A costs . . . .” (¶ 183.)

Fortrea later explained that those projects had “a lot of hours in them already,” resulting in a

“slower burn”—“[i]t’s not so much less backlog; it’s slower burn.” (¶¶ 24, 280.)

ARGUMENT

To state a claim under Section 10(b), Plaintiffs must allege, among other things: (1) a

material misstatement or omission; (2) scienter; and (3) loss causation. See Singh v. Cigna Corp.,

918 F.3d 57, 62 (2d Cir. 2019); In re Philip Morris Int’l Inc. Sec. Litig., 89 F.4th 408, 417 (2d Cir.

2023). Plaintiffs must also satisfy the heightened pleading requirements of Rule 9(b) and the

PSLRA, which require that the Complaint plead the circumstances constituting the alleged fraud

with particularity. See ATSI Commc’ns, Inc., 493 F.3d at 99; Philip Morris, 89 F.4th at 416-17; In

re DRDGOLD Ltd. Sec. Litig., 472 F. Supp. 2d 562, 567 (S.D.N.Y. 2007).

Case 1:25-cv-04630-KPF Document 64 Filed 01/28/26 Page 16 of 36

I. PLAINTIFFS FAIL TO PLEAD THE EXISTENCE OF AN ACTIONABLE
MISSTATEMENT OR OMISSION

Plaintiffs identify allegedly false or misleading statements falling into two categories: (i)

statements concerning Fortrea’s TSA exit strategy and anticipated SG&A efficiencies from

moving to “fit-for-purpose” infrastructure (¶¶ 208-46), and (ii) statements concerning Fortrea’s

PSP backlog and future revenue visibility. (¶¶ 196-207.) Plaintiffs have not adequately pleaded

that any statement is actionable.3

To meet the heightened pleading standard of the PSLRA, a plaintiff must “specify each

statement alleged to have been misleading” and “the reason or reasons why the statement is

misleading.” 15 U.S.C. § 78u-4(b)(1). Whether a statement is misleading must be assessed “in

light of all its surrounding text,” “in its full context,” and from the perspective of a “reasonable

investor.” Omnicare, Inc. v. Laborers Dist. Council Constr. Indus. Pension Fund, 575 U.S. 175,

190 (2015). A plaintiff must plead particularized facts showing that challenged statements were

false or misleading when made, not merely that later developments disappointed expectations.

See In re Nokia Corp. Sec. Litig., 2021 WL 1199030, at *14 (S.D.N.Y. Mar. 29, 2021).

Allegations of “fraud by hindsight” are insufficient as a matter of law. Slayton v. Am. Express

Co., 604 F.3d 758, 776 (2d Cir. 2010).

3
To the extent Plaintiffs assert scheme liability under Rule 10b-5(a) or (c), that claim fails because Plaintiffs
allege no deceptive conduct apart from the alleged misstatements and omissions, which must be analyzed under
Rule 10b-5(b). SEC v. Rio Tinto plc, 41 F.4th 47, 54-55 (2d Cir. 2022).

Case 1:25-cv-04630-KPF Document 64 Filed 01/28/26 Page 17 of 36

A. The Vast Majority of the Challenged Statements
Are Inactionable Forward-Looking Statements

As a threshold issue, the vast majority of the statements challenged by Plaintiffs are

forward-looking statements protected by the PSLRA safe harbor,4 which makes such statements

inactionable if (1) the statement is identified as forward-looking and accompanied by meaningful

cautionary language, or (2) the plaintiff fails to plead facts showing that the speaker made the

statement with actual knowledge that it was false or misleading. 15 U.S.C. § 78u-5(c)(1). The

safe harbor is “written in the disjunctive.” Slayton, 604 F.3d at 766

Here, both the TSA and PSP challenged statements are forward-looking on their face,

including those concerning expected future revenue visibility, anticipated margin improvement,

targeted EBITDA levels, the expected timing and impact of exiting TSAs, and anticipated

benefits from moving to “fit-for-purpose” infrastructure. (¶¶ 196, 200, 206, 208, 212, 214, 216,

218, 220, 222, 224, 226, 228, 230, 232, 234, 237, 239, 241, 243, 245.)5 Likewise, Plaintiffs cite

to statements concerning targets or goals about future performance, including references to

“revenue in years to come” (¶ 196), “confidence and visibility into our future revenues” (¶ 200),

“expect[ations] to be on track with . . . exiting 2024 . . . at a run rate around a 13% EBITDA

margin” (¶ 222), improvements expected to emerge “over time,” “in phases” and “through the

year” (¶¶ 208, 212, 216, 236, 239, 241), and SG&A efficiencies tied to replacing TSAs with

4
Each source of the challenged statements expressly identified them as “forward-looking statements” subject to
significant risks and uncertainties that could cause actual results to differ materially from our current
expectations” and incorporated Fortrea’s risk disclosures filed with the SEC. (See, e.g., Exs. G, H, I, J at 2; Ex.
K at 2, 7; Ex. F at 1, 5.)
5
Plaintiffs identify one statement they contend encompassed a representation of present fact in their pre-motion
letter (ECF No. 55 (“PML”) at 2, citing ¶ 204.), That statement is inactionable puffery and not alleged to be
false. Plaintiffs’ reliance on In re Chicago Bridge & Iron Co. N.V. Sec. Litig., 2018 WL 2382600 (S.D.N.Y.
May 24, 2018) therefore is unavailing. See id. at *8 (statements included present facts). And, as explained
below, Plaintiffs have not identified any omissions, rendering the remainder of their citations inapposite. See
City of Providence v. Aeropostale, Inc., 2013 WL 1197755, at *12 (S.D.N.Y. Mar. 25, 2013); In re Estée
Lauder Co., Inc. Sec. Litig., 2025 WL 965686, at *7 (S.D.N.Y. Mar. 31, 2025).

Case 1:25-cv-04630-KPF Document 64 Filed 01/28/26 Page 18 of 36

“more fit-for-purpose infrastructure” (¶ 208, 218). Because these statements are quintessential

forward-looking statements, they cannot form the basis of securities fraud under the PSLRA safe

harbor. See Docdeer Found. v. BioNTech SE, 2025 WL 2781381, at *12-13 (S.D.N.Y. Sept. 30,

2025) (“[P]rojections of revenue or income and future economic performance” are forward-

looking statements.)

1. These Forward-Looking Statements Were Accompanied By
Meaningful Cautionary Language

With respect to the TSA exits and forecasted future cost improvements, Fortrea

cautioned its “dependence on third parties” and “ability to establish and develop” systems could

“cost more or take longer than anticipated.” (Ex. B at 4.) With respect to the PSPs and backlog,

Fortrea cautioned that its “backlog . . . may not be indicative of [its] future revenues and [it]

might not realize all of the anticipated future revenue reflected in [its] backlog.” (Id.) Fortrea

included specific disclosures concerning the very risks about which Plaintiffs complain.6 The

cited statements therefore are inactionable pursuant to the safe harbor. See, e.g., Ark. Pub. Emps.

Ret. Sys. v. Bristol-Myers Squibb Co., 28 F.4th 343, 355, 357 (2d Cir. 2022) (affirming dismissal

where “the relevant risk . . . was fully disclosed.”); In re Weight Watchers Int’l Inc. Sec. Litig.,

6
Plaintiffs argue that the safe harbor is inapplicable because the risks supposedly already had transpired,
asserting that the supposed fact that “the PSPs had ‘a lot of hours in them’” and one vendor “was chronically
over budget” already existed. (PML at 3.) Plaintiffs’ allegations of falsity, however, concern statements about
future SG&A savings, margin improvement and revenue generation from backlog, not the specific number of
hours on projects or the budget for a vendor. This distinction is illustrated by the case Plaintiffs cite. See
Rombach v. Chang, 355 F.3d 164, 173-74 (“A company that operates 119 separate facilities nationwide is
bound to have problems assimilating this or that property, to have disputes over payments with vendors and
landlords, and to have some bills unpaid by reason of contested amounts or spot episodes of illiquidity; the
allegations in the complaint are consistent with unremarkable circumstances short of financial peril or
instability.”).

Case 1:25-cv-04630-KPF Document 64 Filed 01/28/26 Page 19 of 36

504 F. Supp. 3d 224, 255 (S.D.N.Y. 2020) (warnings “disclose[d] the exact risk of which

Plaintiffs complain”).7

2. Plaintiffs Have Not Pled Defendants Had Actual Knowledge That The
Statements Were False

To plead actual knowledge under the PSLRA’s safe harbor, Plaintiffs must allege

particularized facts showing that Defendants knew their statements were false or misleading

when made. 15 U.S.C. § 78u-5(c)(1)(B)(i). “[T]he scienter requirement for forward-looking

statements is stricter than for statements of current fact.” Slayton, 604 F.3d at 773. To meet this

high standard, Plaintiffs must allege “specific, contemporaneous reports or statements”

demonstrating that Defendants did not believe their stated expectations or knew that the

projections were unattainable when made. In re Danimer Sci., Inc. Sec. Litig., 2023 WL

6385642, at *7 (E.D.N.Y. Sept. 30, 2023), ) aff’d sub nom. Swanson v. Danimer Sci., Inc., 2024

WL 4315109 (2d Cir. Sept. 27, 2024; see also S.S. Trade Ass’n of Balt.-Int’l Longshoreman’s

Ass’n Pension Fund v. Olo Inc., 704 F. Supp. 3d 429, 443-44 (S.D.N.Y. 2023). Allegations that

Defendants may have known of some issues affecting future performance are insufficient. See

Slayton, 604 F.3d at 776.

Here, Plaintiffs claim that Defendants approved budget overages for a vendor and had

seen an unidentified model in 2023 that projected cost savings from a particular project would

take three years to realize. (PML at 3, citing ¶ 159.) But, as explained in more detail below (see

infra § II.C), Plaintiffs’ former employee (“FE”) allegations do not establish the falsity of any

statement, let alone that anyone knew the statements were false when made. Rather, the FE

7
Fortrea’s risk disclosures are far more specific that the “general warnings in AMC’s SEC forms, about
‘execution risks’ relating to AMC’s acquisitions [and] unspecified ‘known . . . risks [and] uncertainties’” at
issue in the case cited by Plaintiffs. See Haw. Structural Ironworkers Pension Trust Fund v. AMC Ent.
Holdings, Inc., 422 F. Supp.3d 821, 847 (S.D.N.Y. 2019) (alterations in original).

Case 1:25-cv-04630-KPF Document 64 Filed 01/28/26 Page 20 of 36

allegations either are consistent with Fortrea’s public statements, or fail to speak to the issues

alleged by Plaintiffs. Plaintiffs have not shown with specificity that Defendants had acted with

actual knowledge that the statements were false or misleading.8

B. Plaintiffs’ TSA Allegations Do Not Identify
Any Actionable Misstatement or Omission

Plaintiffs allege Fortrea purportedly failed to disclose that TSA services would be

replaced with similar, if not higher costs, and that internal cost models allegedly showed that

certain replacement arrangements would take years to yield savings. (¶¶ 209, 223-46.) Plaintiffs

further contend that several statements misleadingly suggested that exiting the TSAs was the

primary constraint on reducing SG&A and achieving margin improvement. (¶ 238.)

In evaluating the statements at issue, a court should consider the actual statements and

surrounding context, not plaintiff’s characterization of the statements. See In re Express Scripts

Holdings Co., 773 F. App’x 9, 12 (2d Cir. 2019); Martin v. Quartermain, 732 F. App’x 37, 41-

42 (2d Cir. 2018); Singh, 918 F.3d at 63; see also In re IAC/InterActiveCorp Sec. Litig., 478 F.

Supp. 2d 574, 585 (S.D.N.Y. 2007) (“Nor should a court accept allegations that are contradicted

or undermined by other more specific allegations in the complaint or by written materials

properly before the court.”). Here, Plaintiffs have failed to allege that a single TSA statement

was false when made.

First, Plaintiffs attempt to assert falsity by claiming that because Labcorp provided

services at cost (which was disclosed), exiting the TSAs “would not cause the Company’s

SG&A to decrease.” (¶ 157.) From this faulty premise, Plaintiffs allege the falsity of numerous

8
Again, the facts alleged here can be contrasted with the case relied upon by Plaintiffs (PML at 3), where the
former employee was alleged to have reported the items at issue directly to the Chief Executive Officer. See In
re STMicroelectronics N.V. Sec. Litig., 2025 WL 2644241, at *2 (S.D.N.Y. Sept. 15, 2025).

Case 1:25-cv-04630-KPF Document 64 Filed 01/28/26 Page 21 of 36

statements, claiming that exiting the TSAs “would merely result in replacing TSA service costs

with similar, if not higher, infrastructure costs from Fortrea itself for third-party service

providers.” (See ¶¶ 209, 211, 213, 215, 217, 219, 223, 225, 227, 229, 231, 233, 235, 240, 242,

244, 246.) But Plaintiffs’ claims rewrite Fortrea’s disclosures, which do not promise an

instantaneous reduction of SG&A expense upon exiting a TSA,9 but instead explain that Fortrea

expected future SG&A improvements as it replaced TSAs “with more fit-for-purpose

infrastructure” and that margin improvements would occur “over time.” (¶ 208.) Indeed, as

Plaintiffs concede, Fortrea explained that “[t]he improvements will come in phases over the next

few years” (¶ 212) and that “owners have been tasked with coming back with a replacement

system or technology or process that is more cost effective.” (¶ 220; see also ¶¶ 210, 214, 216,

218, 226, 228, 230, 234, 237, 239, 241, 243, 245.) Read in context, Fortrea clearly explained that

exiting the TSAs would open the door to a more cost optimized structure as Fortrea implemented

newly designed fit-for-purpose systems allowing it to operate more efficiently.10 Thus, Plaintiffs’

bald allegations that the statements were false because replacing the TSA would result in

“similar, if not higher, infrastructure costs” from a “third-party service provider” (¶¶ 215, 217,

219)–or suggestion that Labcorp’s systems could not be improved upon because they were

provided at cost (¶¶ 223, 242, 246)–are misaligned with Fortrea’s actual disclosures, which

speak to an ongoing process that would allow improved efficiencies from the newly developed

systems (Compare ¶ 12 (incorrectly asserting that Defendants’ statements could only be true if

9
There would be some improvement in expenses as exiting the TSAs would mean that Fortrea no longer would
need to pay both for the TSA and the design and implementation of its new systems.
10
Fortrea’s characterization of exiting the TSAs as being “key,” “critical,” or “essential” to future margin
improvement (¶¶ 218, 220, 228, 230, 245) are consistent. These statements do not assert that TSA exit was the
sole driver of margin improvement, nor do they represent that TSA exit alone would guarantee cost reductions.

Case 1:25-cv-04630-KPF Document 64 Filed 01/28/26 Page 22 of 36

they could “implement services cheaper than at the cost provided by Labcorp.”); see also ¶¶ 97,

138, 139.)

Second, Plaintiffs recast their mistaken claim that the TSAs could not be improved upon

into allegations that any forecast about SG&A or margin improvements also must have been

false when made. Many of the statements identified by Plaintiffs, however, speak about future

SG&A or margin improvement, following exit from the TSAs and implementation of the new fit-

for-purpose systems. (See, e.g., ¶ 212 (“improvements will come in phases over the next few

years”); ¶ 218 (2024 “is really how do we make sure we exit those TSAs, start moving towards a

more fit-for-purpose infrastructure”); ¶ 228 (“TSA exits allow us to start to make some of the

more significant changes around SG&A”); ¶ 239 (potential to improve SG&A “over time once

we fully exit the TSA services and can transition to lower cost replacement infrastructure”); see

also ¶¶ 208, 210, 214, 220, 224, 230, 234, 237, 241, 245.) Contrary to Plaintiffs’ allegations,

Fortrea’s disclosures speak to the development of a fit-for-purpose structure that would lead to

potential future efficiencies.11

Third, Plaintiffs’ attempt to bootstrap their TSA arguments into an assertion that SG&A

or margin forecasts must have been false when made ignores Fortrea’s actual disclosures and the

components of the ratios they cite. Margin includes both revenue and adjusted EBITDA, both of

which involve many metrics beyond TSA exits. (See ¶ 171 (net income to adjusted EBITDA

11
Plaintiffs term this argument “puzzling” in their pre-motion letter (PML at 1 n.2), asserting that “Defendants
also repeatedly assured investors that the TSA Exit Strategy would reduce expenses, leading to 13% EBITDA
margins ‘exiting 2024’ and that the ‘TSA exit trajectory’ was ‘really key to unlocking the SG&A
improvement.” (Id. at 1-2 (citations omitted).) The disclosures they cite, however, contain no such assurances.
(See ¶ 222 (discussing “headwinds of lower full-service clinical sales, elevated infrastructure costs and the
transition services agreement” and continues to state that the Company was “working to mitigate these
headwinds and we expect to be on track with the previously shared margin improvement target of exiting 2024
and entering 2025 at a run rate around 13% adjusted EBITDA margin.”); ¶ 230 (“there’s a lot of opportunity in
SG&A and exiting those TSAs at the tail end of this year will give us that opportunity for 2025”); ¶ 239
(potential margin improvement “over time once we fully exit the TSA services and can transition to lower cost
replacement infrastructure.”).)

Case 1:25-cv-04630-KPF Document 64 Filed 01/28/26 Page 23 of 36

reconciliation).)12 Likewise, the ratio of SG&A expense to revenue axiomatically is driven in

significant part by revenue.13 And the forward-looking margin forecasts about which Plaintiffs

complain reflect that Fortrea expected near term margin improvements to come from areas other

than TSA exits. (See ¶ 222 (efforts to mitigate “headwinds of lower full-service clinical sales,

elevated infrastructure costs and the transition services agreement”); ¶ 224 (margin forecast

assumes “quarterly book-to-bill metrics of at least 1.2x and exiting our TSAs per our current

plans.”); ¶ 226 (margin growth in back half of 2024 “weighted a little bit more to revenue

growth”); ¶ 237 (most margin improvement would come from gross margin “because the

Company would not yet have exited the TSAs.”).)14 That Fortrea later revised its margin forecast

does not make any of these statements false.

Fourth, Fortrea explained that exiting individual TSAs would not, standing alone, drive

margin improvement because “it’s really what we replace them with.” (¶ 220.) Where a company

discloses execution risk and that risk later materializes, the securities laws do not impose

liability. See Lentell v. Merrill Lynch & Co., 396 F.3d 161, 177 (2d Cir. 2005); Merrill Lynch &

Co., 568 F. Supp. 2d 349, 360 (S.D.N.Y. 2008).15

12
Plaintiffs’ observation that adjusted EBITDA was reported “without the impact of ‘one-time’ costs” (¶ 173) is
consistent. Adjusted EBITDA margin improvements can be driven by many factors unrelated to TSA exits.
13
SG&A cost improvements also were not limited to TSA exits. (See ¶ 232 (“we’re pushing even harder on
expense controls and cost improvements in operations and SG&A.”)).
14
Although Plaintiffs attempt to disguise it by focusing on ratios, Plaintiffs’ chart reflects that SG&A expense did
decrease in the first quarter of 2025, as did its TSA expense. (See ¶ 84.)
15
Although largely beside the point, see In re Skechers USA, Inc. Sec. Litig., 444 F. Supp. 3d 498, 521 (S.D.N.Y.
2020) (analyst reports cannot make non-actionable statements actionable), Plaintiffs also misportray analyst
commentary. William Blair cautioned that Fortrea’s margin outlook carried significant “execution risk.” (Ex. L
at 1.) Jefferies similarly emphasized that margin improvement depended on revenue productivity rather than
cost cutting alone. (Ex. M at 1.) Deutsche Bank likewise noted that “[n]ear term margins” would remain
pressured, with “the majority of SG&A improvement” expected in 2025. (Ex. N at 2.).

Case 1:25-cv-04630-KPF Document 64 Filed 01/28/26 Page 24 of 36

Fifth, Plaintiffs’ alternate attempt to cast their claim as one of omission fails. Plaintiffs

claim that Fortrea failed to disclose that TSA services would be replaced with similar, if not

higher costs. (¶¶ 209, 211, 213, 215, 217, 219, 221, 223.) Setting aside that the fact that

Labcorp’s service under the TSA was provided at cost was fully disclosed (see supra),16

additional disclosure is required “only when necessary to make . . . statements made, in the light

of the circumstances under which they were made, not misleading.” Macquarie Infrastructure

Corp. v. Moab Partners, L.P., 601 U.S. 257, 264 (2024). “Whether a statement is misleading

must be assessed “in light of all its surrounding text,” “in its full context,” and from the

perspective of a “reasonable investor.” Omnicare, Inc., 575 U.S. at 190. Plaintiffs’ omission

theory fails for the very same reason as its misstatement theory: Fortrea’s disclosures were not

false when made, and no further disclosure was necessary to make them not misleading. See

Bratusov v. Comscore, Inc., 2020 WL 3447989, at *10-12 (S.D.N.Y. June 24, 2020) (Failla, J.).17

In the end, to plead a claim for securities fraud Plaintiffs must plead particularized facts

showing challenged statements “were false or misleading when made.” Rombach, 355 F.3d at

175. They have not done so. And pleading fraud by hindsight, which is all Plaintiffs have done,

is insufficient as a matter of law. Bay Harbour Mgmt. LLC v. Carothers, 282 F. App’x 71, 75 (2d

Cir. 2008).

16
“Even at the pleading stage, dismissal is appropriate where the complaint is premised on the nondisclosure of
information that was actually disclosed.” In re Keyspan Corp. Sec. Litig., 383 F. Supp. 2d 358, 377 (E.D.N.Y.
2003).
17
As explained in the case cited by Plaintiffs, “[w]e do not understand these references to the ‘whole truth’ and to
speaking ‘completely’ to describe a duty to disclose all the facts that pertain to a subject (many of which would
be immaterial), but instead to describe a duty not to omit material facts whose omission, in light of what was
stated, would be misleading.” Setzer v. Omega Healthcare Inv., Inc., 968 F.3d 204, 214 n.15 (2d Cir. 2020).

Case 1:25-cv-04630-KPF Document 64 Filed 01/28/26 Page 25 of 36

C. Plaintiffs’ PSP Allegations Do Not
Identify Any Actionable Misstatement or Omission

Plaintiffs’ allegations concerning PSP backlog fare no better. Two of those predate the

putative class period and cannot be the source of a securities fraud claim. (See ¶¶ 196, 200). See

Lattanzio v. Deloitte & Touche LLP, 476 F.3d 147, 153 (2d Cir. 2007); In re Lions Gate Ent.

Corp. Sec. Litig., 165 F. Supp. 3d 1, 16-17 (S.D.N.Y. 2016); In re Openwave Sys. Sec. Litig., 528

F. Supp. 2d 236, 253-54 (S.D.N.Y. 2007). In any event, those statements, as well as the

remaining three, distill to statements that Fortrea had a backlog of a specified amount (¶¶ 204,

206), had contracts that extended over multiple years (¶¶ 196, 200) and had restated its backlog

to remove projects with no current revenue and to incorporate known scope changes. (¶ 202.)

None of these statements is alleged to be false.

Plaintiffs do not dispute the accuracy of Fortrea’s disclosed backlog metrics, nor that

Fortrea had contracts that extended for multiple years. Indeed, Plaintiffs admit that Fortrea

converted significant backlog into revenue during the putative class period. (¶ 59.) See Docdeer

Found., 2025 WL 2781381, at *12 (accurate historical information does not create implicit

promise as to future success). Plaintiffs also do not dispute that Fortrea restated its backlog in

2023 as part of the spinoff to remove contracts that no longer had current revenue.18

Instead, Plaintiffs purport to show falsity by pointing to a later disclosure “that the pre-

spin projects, many late in their lifecycle, have less revenue and less profitability expected for

2025,” which Fortrea further explained: “[i]t’s not so much less backlog; it’s slower burn and

that’s the difference in ‘25” and that certain contracts “have a lot of hours in them already, and

every incremental hour is less as a percentage of the total, and that causes them to burn more

18
Removing contracts that have no current revenue from the backlog is far different than forecasting which
contracts might experience slower that expected burn years in the future.

Case 1:25-cv-04630-KPF Document 64 Filed 01/28/26 Page 26 of 36

slowly.” (¶ 280; see also ¶¶ 201, 203, 205, 207.) That the backlog conversion in 2025 turned out

differently than expected does not demonstrate the falsity of any of these statements. See Novak

v. Kasaks, 216 F.3d 300, 309 (2d Cir. 2000); In re Lululemon Sec. Litig., 14 F. Supp. 3d 553, 571

(S.D.N.Y. 2014), (“A statement believed to be true when made, but later shown to be false, is

insufficient.”), aff’d, 604 F. App’x 62 (2d Cir. 2015).

Moreover, Fortrea expressly warned that backlog is “not” a “consistent indicator of future

revenue” and is affected by “the variable size and duration of projects.” (Ex. B, FY23 Form 10-K

at 50.) Fortrea also cautioned investors throughout the class period about the “need to expend

significant efforts and costs” to replace TSAs. (Id.; see also Ex. A at 26 (“including potentially

materially in excess of those estimated in the transition services agreement”.) Indeed, Fortrea

further explained in its 2024 quarterly filings that revenue pressure reflected the mix and burn

rate of PSPs. (Ex. C at 39; Ex. D at 36.) Materialization of a disclosed risk does not constitute

securities fraud. Lentell, 396 F.3d at 177; Smith v. PureCycle Techs., Inc., No. 23-CV-8605

(JGK), 2024 WL 5186586, at *9-10 (S.D.N.Y. Dec. 20, 2024).

Plaintiffs’ reliance on an unidentified FE who purportedly worked in “Technology

Engagement” for less than a year who allegedly stated that it was “well known . . . that the trials

and other projects associated with the Pre-Spin Projects had little work left on them” and “was

not producing enough revenue to carry the Company” does not alter the analysis. (¶¶ 72-73.) FE1

is not alleged to have opined that Fortrea included anything inappropriate in its disclosed backlog

figures. Rather, FE1 complains that the PSPs were “not producing enough revenue to carry the

Company”(¶ 73) and that FE1 wanted but did not receive “more color on the Company’s

pipeline of new contracts.” (¶ 74.) Fortrea, however, is not alleged to have stated that the PSP

Case 1:25-cv-04630-KPF Document 64 Filed 01/28/26 Page 27 of 36

contracts were sufficient to “carry” the Company, and Plaintiffs complain about the backlog, not

pipeline.

Nor have Plaintiffs identified an actionable omission relating to the PSPs. In sweeping

fashion, Plaintiffs conclude that each of the PSP statements was false because Fortrea

purportedly failed to disclose “that the Pre-Spin Projects, many late in their lifecycle, already had

‘a lot of hours in them’ and, under their terms, would provide less revenue and less profitability

on an annual basis going forward.” (¶ 205; see also ¶¶ 197, 201, 203, 207.) But a plaintiff must

plead particularized facts showing that challenged statements were false or misleading when

made, not merely that later developments disappointed expectations. Rombach, 355 F.3d at 175;

Shemian v. Rsch. In Motion Ltd., 2013 WL 1285779, at *21 (S.D.N.Y. Mar. 29, 2013), (plaintiffs

must plead “sufficient facts regarding the existence and timing of Defendants’ knowledge of

defects to give rise to a duty to disclose.”) aff’d, 570 F. App’x 32 (2d Cir. 2014). Absent from the

Complaint is any particularized allegation that Fortrea knew that it would later come to pass that

certain projects were burning more slowly than had been anticipated based on then-available

information. Plaintiffs also have failed to allege that any of the truthful statements made by

Fortrea about its backlog were rendered false by an alleged omission. A plaintiff must plead a

“direct connection between Defendants’ statements” and the allegedly omitted facts. In re ITT

Educ. Servs., Inc. Sec. & S’holder Derivatives Litig., 859 F. Supp. 2d 572, 579 (S.D.N.Y. 2012);

see also In re DraftKings Inc. Sec. Litig., 650 F. Supp. 3d 120, 169 n.20 (S.D.N.Y. 2023). Here,

the alleged omissions are disconnected from Fortrea’s statements about the size of the backlog

(which Plaintiffs do not dispute) or the fact that many of Fortrea’s contracts were multiple year

contracts (which Plaintiffs also do not contest).

Case 1:25-cv-04630-KPF Document 64 Filed 01/28/26 Page 28 of 36

D. Fortrea’s Statements of Corporate Optimism or Opinion Are Not Actionable

Many of the challenged statements also fail to state a claim for additional reasons.

Statements describing Fortrea as “a great partner” and “a long-term value creation opportunity”

(¶ 204), having “confidence and visibility into [its] future revenues” (¶ 200), having an

“attractive” backlog or is “commit[ed] to longer-term growth.” (¶ 206) are classic examples of

“vague pronouncements of corporate optimism” In re Nokia Corp. Sec. Litig., 2021 WL

1199030, at *17 n.16, that “cannot have misled a reasonable investor.” ECA, Loc. 134 IBEW

Joint Pension Tr. of Chicago v. JPMorgan Chase Co., 553 F.3d 187, 206 (2d Cir. 2009); see also

Docdeer Found., 2025 WL 2781381, at *14 (statements describing an “expanded broad pipeline”

were puffery); City of Warren Police & Fire Ret. Sys. v. Foot Locker, Inc., 412 F. Supp. 3d 206,

221 (E.D.N.Y. 2019).19

Likewise, Plaintiffs’ attempt to challenge statements of opinion also fails. (See ¶¶ 118,

175, 224, 234, 245.) To plead a claim based on an opinion, a plaintiff “must identify particular

(and material) facts going to the basis for the issuer’s opinion—facts about the inquiry the issuer

did or did not conduct or the knowledge it did or did not have—whose omission makes the

opinion statement at issue misleading to a reasonable person reading the statement fairly and in

context.” Tongue v. Sanofi, 816 F.3d 199, 209 (2d Cir. 2016) (quoting Omnicare, Inc., 575 U.S.

at 194). An opinion “is not necessarily misleading when an issuer knows, but fails to disclose,

19
The cases cited by Plaintiffs are not to the contrary. See SEC v. Farnsworth, 692 F. Supp. 3d 157, 181
(S.D.N.Y. 2023) (Failla, J.) (statements were “attempts to address concerns about specific elements of the
Companies’ financial situation and business model, rather than general boasting of general characteristics about
the business”); In re Virtu Fin., Inc. Sec. Litig., 770 F. Supp. 3d 482, 501 (E.D.N.Y. 2025) (“To ascertain
whether the challenged statements are ‘determinate, verifiable statements,’ as opposed to puffery, courts look
for an ‘objective, black-and-white standard.’”); In re Petrobras Sec. Litig., 116 F. Supp. 3d 368, 381 (S.D.N.Y.
2015) (statements “were made repeatedly in an effort to reassure the investing public about the Company’s
integrity”). Indeed, there are no allegations that the Company was not on track for exiting the TSAs by the end
of 2024 (¶¶ 118, 175, 245) or that a streamlined cost structure would not enable the Company to reduce SG&A
expenses. (¶¶ 224, 234.)

Case 1:25-cv-04630-KPF Document 64 Filed 01/28/26 Page 29 of 36

some fact cutting the other way.” Id. at 210.20 For the reasons explained above, Plaintiffs have

failed to plead with particularity that any of the opinion statements were known to be false at the

time they were made.

II. PLAINTIFFS FAIL TO ALLEGE A STRONG INFERENCE OF SCIENTER

Although the Court need not reach the issue, Plaintiffs’ claims fail for the independent

reason that they have not pled “with particularity facts giving rise to a strong inference” that each

Defendant acted with scienter, i.e., “an intent ‘to deceive, manipulate, or defraud.’” ECA, 553 F.

3d at 206 (quoting Tellabs, Inc. v. Makor Issues & Rights, Ltd., 551 U.S. 308, 313 (2007)). To

meet the onerous pleading standard, the inference of scienter “must be ‘more than merely

plausible or reasonable—it must be cogent and at least as compelling as any opposing inference

of nonfraudulent intent.’” Id. Plaintiffs must allege particularized facts showing either (1) that

defendants had the motive and opportunity to commit fraud, or (2) strong circumstantial

evidence of conscious misbehavior or recklessness.” ECA, 553 F.3d at 198. Plaintiffs make no

effort to show motive—there are no allegations of specific stock sales or other personal gains—

and Plaintiffs’ attempt to show conscious misbehavior or recklessness falls flat.

A. Plaintiffs’ Miscellaneous Allegations
Do Not Give Rise to a Strong Inference of Scienter

Unable to show motive, Plaintiffs resort to a hodgepodge of allegations distilling to a

legally insufficient claim that the Defendants should have known of the falsity of their

statements. Glaser v. The9, Ltd., 772 F. Supp. 2d 573, 588 (S.D.N.Y. 2011). To plead scienter,

however, “Plaintiffs would have to show, at the least, conduct which is highly unreasonable and

20
Unlike the cases cited by Plaintiffs, there are no facts pled establishing that the Defendants did not believe the
statements were true. See Abramson v. Newlink Genetics Corp., 965 F.3d 165, 177 (2d Cir. 2020); Fresno Cnty.
Emps.’ Ret. Ass’n v. comScore, Inc., 268 F. Supp. 3d 526, 547 (S.D.N.Y. 2017).

Case 1:25-cv-04630-KPF Document 64 Filed 01/28/26 Page 30 of 36

which represents an extreme departure from the standards of ordinary care.” ECA, 553 F.3d at

202-03. They have not done so.

First, Plaintiffs’ “core operations” argument fails, (see ¶ 255), as “[c]ourts have required

that the operation in question constitute nearly all of a company’s business . . . .’” In re Barrick

Gold Corp. Sec. Litig., 341 F. Supp. 3d 358, 374 (S.D.N.Y. 2018) (finding company’s largest

mine, accounting for 70% of gold production, insufficient). Clinical development contracts

constitute Fortrea’s business—not transitional service agreements. (See ¶¶ 43-44.) Regardless,

the core operations doctrine “does not independently establish scienter.” Lipow v. Net1 UEPS

Techs., Inc., 131 F. Supp. 3d 144, 163 (S.D.N.Y. 2015); see also Docdeer Found., 2025 WL

2781381, at *16.

Nor can Plaintiffs allege scienter based on Defendants’ high-level positions. (See ¶¶ 38,

249.) See also In re Farfetch Ltd. Sec. Litig., 802 F. Supp. 3d. 652 (S.D.N.Y. 2025); Lipow, 131

F. Supp. 3d at 163. Even taken together, allegations based on core operations and high-level

positions are too “general” and therefore “undisputedly insufficient to satisfy the heightened

pleading standard.” Campo v. Sears Holdings Corp., 635 F. Supp. 2d 323, 336 (S.D.N.Y. 2009),

aff’d, 371 F. App’x 212 (2d Cir. 2010); see also Barrick Gold Corp., 341 F. Supp. 3d at 373. Nor

can Plaintiffs cure these defects by alleging, in general terms, that certain information was

available through internal systems or models. See Loc. No. 38 Int’l Bhd. of Elec. Workers

Pension Fund v. Am. Express Co., 724 F. Supp. 2d 447, 461 (S.D.N.Y. 2010), aff’d, 430 F.

App’x 63 (2d Cir. 2011); In re Citigroup Inc. Sec. Litig., 753 F. Supp. 2d 206, 245 (S.D.N.Y.

2010).

Plaintiffs’ last-ditch effort to cast Defendant Pike’s resignation in May 2025—months

after any purported materialization of disclosed risk—as evidence of scienter also is legally

Case 1:25-cv-04630-KPF Document 64 Filed 01/28/26 Page 31 of 36

insufficient. (¶ 261); Wilbush v. Ambac Fin. Grp., Inc., 271 F. Supp. 3d 473, 499 (S.D.N.Y.

2017) (resignations were not “‘highly unusual [or] suspicious’ when defendants ‘resigned . . .

several months after the Class Period ended’”); see also Bratusov, 2020 WL 3447989, at *15.

B. The Former Employee Allegations Do Not Establish Scienter

Plaintiffs additionally attempt to use confidential witness allegations as the basis to

establish scienter. (¶¶ 145-59, 258.) As a threshold issue, Plaintiffs do not describe these

purported sources “with sufficient particularity to support the probability that a person in the

position occupied by the source would possess the information alleged.” Novak, 216 F.3d at 314;

Damri v. LivePerson, Inc., 772 F. Supp. 3d 430, 450-51 (S.D.N.Y. 2025). None of the FEs is

alleged to have held a position that would plausibly provide insight into Fortrea’s senior-level

decision-making, 21 nor do Plaintiffs allege that any FE had direct discussions with or attended

any meeting with the Individual Defendants. See Meyer v. Organogenesis Holdings Inc., 727 F.

Supp. 3d 368, 396 (E.D.N.Y. 2024); Loc. No. 38, 724 F. Supp. 2d at 460 (rejecting “anecdotes

and conclusory statements” from “rank-and-file” employees); Jackson v. Halyard Health, Inc.,

2018 WL 1621539, at *9 (S.D.N.Y. Mar. 30, 2018) (“Plaintiffs’ vague references to ‘senior

leadership’ and ‘senior management’ do not suffice to tie the Individual Defendants to any

information that was conveyed.”); Glaser, 772 F. Supp. 2d at 591 (“[C]onclusory statements that

defendants ‘were aware’ of certain information . . . or ‘should have’ had such knowledge is

insufficient”).

21
Plaintiffs claim that FE1 participated in weekly “TSA Steering Committee” meetings, which included the Chief
Information Officer who in turn, “was a direct report of defendant Pike and a colleague of defendant
McConnell[.]” (¶ 145.) Plaintiffs claim this made “FE1 just one level removed from the Individual Defendants.”
(Id.) FE2, allegedly a procurement employee, appears even further removed. (See ¶ 156 (FE2 “voiced concerns
to their direct superior and Fortrea’s Chief Procurement Officer[.]”).)

Case 1:25-cv-04630-KPF Document 64 Filed 01/28/26 Page 32 of 36

Even if the FE allegations could be credited, they do not establish scienter. At most, FE1

is alleged to have stated that the Company was overbudget on costs paid to one vendor because

the vendor was “nickel-and-diming” the Company and that the Company signed off on certain

budget overages. (¶ 148.) Even taken at face value, these allegations say nothing about Fortrea’s

strategy of attempting to reduce SG&A expense over time as the TSA exits occurred or how the

supposed “nickel-and-diming” impacted any forecast or disclosed metric. Likewise, FE2 is

alleged to have disagreed with the retention of a vendor and to have seen an unspecified cost

model showing that the shift to a vendor would take three years to realize cost savings. (¶ 159.)

But the purported model22 would have been consistent with the Company’s statements that

efficiencies would materialize “over the next few years” and “in phases.” (¶ 212; see also ¶¶ 208

239, 241.) As to the backlog, FE1’s assertion that PSP pressures were “common knowledge” (¶¶

73, 258(a)) provides no specific facts explaining who supposedly knew, when they knew, or how

such knowledge could be imputed to Defendants. Courts routinely reject “‘vague and

conclusory’” confidential witness allegations that information was “‘common knowledge within

the company.’” Chapman v. Mueller Water Prods., Inc., 466 F. Supp. 3d 382, 399-400

(S.D.N.Y. 2020) (citations omitted) (“pretty much everyone” was aware); Schiro v. Cemex,

S.A.B. de C.V., 396 F. Supp. 3d 283, 305 (S.D.N.Y. 2019) (“everyone . . . knew”). By contrast,

where confidential witness allegations are credited, they identify concrete internal practices,

specific projects or data, contemporaneous timing, and direct contradictions of public

statements—none of which is alleged here. See Sherman v. Abengoa, S.A., 156 F.4th 152, 160

(2d Cir. 2025).

22
Where Plaintiffs contend Defendants had access to contrary information, they must “specifically identify the
reports or statements containing this information.” In re Pretium Res. Inc. Sec. Litig., 256 F. Supp. 3d 459, 473
(S.D.N.Y. 2017), aff’d, 732 F. App’x 37 (2d Cir. 2018).

Case 1:25-cv-04630-KPF Document 64 Filed 01/28/26 Page 33 of 36

C. Non Culpable Inferences Are More Compelling

Where, as here, Plaintiffs fail to plead motive, fail to identify contemporaneous

contradictory facts, and rely instead on later-disclosed challenges and revised expectations, the

more compelling inference is non-fraudulent: Defendants set targets, encountered operational

challenges, and disclosed results. (See, e.g., ¶¶ 175, 222, 280.) Defendants’ pattern of

contemporaneous risk disclosures, ongoing updates, and eventual revisions is fundamentally

inconsistent with an inference that they acted with intent to deceive. Rombach, 355 F.3d at 176;

In re Nokia Oyj (Nokia Corp.) Sec. Litig., 423 F. Supp. 2d 364, 407 (S.D.N.Y. 2006).

III. PLAINTIFFS FAIL TO PLEAD LOSS CAUSATION

Dismissal is also independently warranted because no causal link connects any alleged

misstatements to any purported loss. See Dura Pharms., Inc, 544 U.S. at 345-46. Plaintiffs

cannot simply point to a price decline following negative news; they must plead facts

demonstrating that the negative news revealed “the truth” about a prior misstatement or

omission. Lentell, 396 F.3d at 177. The loss must be “foreseeable and caused by the

materialization of the risk concealed by the fraudulent statement.” ATSI Commc’ns, Inc., 493

F.3d at 107.

First, the 2Q24 Earnings call did not disclose that any prior statement was false. Rather, it

disclosed only that Fortrea’s transition plans and execution efforts were progressing more slowly

than anticipated—precisely the type of risk Fortrea had repeatedly warned could materialize as a

newly independent company. (See ¶¶ 266-268.) Second, the September 25, 2024 Jeffries Report

Plaintiffs identify as a corrective disclosure is nothing more than “[a] negative . . .

characterization of previously disclosed facts,” which “does not constitute a corrective disclosure

of anything but the [author’s] opinions.” In re Omnicom Grp., Inc. Sec. Litig., 597 F.3d 501, 512

(2d Cir. 2010); Fila v. Pingtan Marine Enter. Ltd., 195 F. Supp. 3d 489, 498 (S.D.N.Y. 2016).

Case 1:25-cv-04630-KPF Document 64 Filed 01/28/26 Page 34 of 36

Third, Plaintiffs also concede that on November 8, 2024—consistent with Fortrea’s prior

disclosures—Fortrea reiterated that exiting the TSAs would not result in “an immediate switch”

to “massively reduced SG&A.” (¶ 175.) There is no alleged stock-price decline that day. And

Plaintiffs’ allegations of price drops on December 6 and 11, 2024 are also untethered to any

corrective disclosure revealing the falsity of the challenged statements. (¶ 272-75.)

Finally, Plaintiffs point to a stock price drop on March 3, 2025, following Fortrea’s

revision of guidance. Fortrea’s revised projections are not corrective disclosures. See Prime

Mover Cap. Partners L.P. v. Elixir Gaming Techs., Inc., 548 F. App’x 16, 18 (2d Cir. 2013)

(revised projections not corrective because it did not reveal a prior misstatement but only

“suggested that defendants had not had reliable information” at the time.) Indeed, Plaintiffs

admit that the relevant information regarding the TSAs already was public by this date. And,

rather than “admit[] that the TSA Exit Strategy was a failure” (¶ 283), Fortrea actually explained,

just as it had stated in the past, that it was moving toward programs designed to reduce expenses

and optimize spend with its own post-TSA enterprise systems. (See Ex. J at 6.) As to the

backlog, Fortrea explained that the alleged “slower burn” of certain pre-spin projects was

identified during Fortrea’s implementation of its new operating environment, not as the

revelation of any previously concealed fact. (¶ 280.) A disclosure describing management’s

discovery of execution dynamics during implementation is not corrective because it does not

“reveal to the market the falsity of the prior [statements].” Prime Mover Cap. Partners L.P., 548

F. App’x at 17.

IV. PLAINTIFF’S SECTION 20(A) CLAIM SHOULD BE DISMISSED

For the reasons described above, Plaintiffs have not sufficiently alleged a primary

violation of Section 10(b) or culpable participation by the Individual Defendants. Accordingly,

the Section 20(a) claim fails. See Docdeer Found., 2025 WL 2781381, at *11.
26

Case 1:25-cv-04630-KPF Document 64 Filed 01/28/26 Page 35 of 36

CONCLUSION
For the foregoing reasons, the Complaint should be dismissed with prejudice.

Dated: New York, New York Respectfully submitted,
January 28, 2026

/s/ Robert A. Fumerton
Susan L. Saltzstein
Robert A. Fumerton
Jeffrey Geier
Eryn M. Hughes

SKADDEN, ARPS, SLATE,
MEAGHER & FLOM LLP
One Manhattan West
New York, New York 10001
Phone: (212) 735-3000
Susan.Saltzstein@skadden.com
Robert.Fumerton@skadden.com
Jeffrey.Geier@skadden.com
Eryn.Hughes@skadden.com

Attorneys for Defendants Fortrea Holdings Inc.,
Thomas Pike, and Jill McConnell

Case 1:25-cv-04630-KPF Document 64 Filed 01/28/26 Page 36 of 36

LOCAL RULE 7.1(C) CERTIFICATION

I, Robert A. Fumerton, hereby certify that the foregoing memorandum of law complies with the

word count limitations set forth in Rule 7.1(c) of the Local Rules of the United States District Court for

the Southern District of New York, and contains 8,750 words, exclusive of the caption, table of

contents, table of authorities, table of exhibits, signature blocks, and this certificate.

Dated: New York, New York
January 28, 2026

/s/ Robert A. Fumerton
Robert A. Fumerton